Vascepa was initially approved by the Food and Drug Administration (FDA) in July 2012 as adjunct to diet to reduce triglyceride (TG) levels in adults with severe (≥500mg/dL) hypertriglyceridemia. The new capsule size is the first half-gram prescription omega-3 option for patients who prefer a smaller capsule.
Vascepa contains omega-3 acid known as eicosapentaenoic acid (EPA) in ethyl ester form. EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.
Vascepa is now available as 0.5g strength capsules in 240-count bottles and 1g strength capsules in 120-count bottles.
For more information call (855) 827-2372 or visit Vascepa.com.